Arcellx Inc (ACLX) Stock Price, Quote & News

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 327 0630

Website: www.arcellx.com

Address:

800 Bridge Parkway, Redwood City, United States

PivotSkull Aug. 23 at 4:36 AM

$ACLX Clinical stage immunology company with novel platform technology but pre-revenue and high cash burn

0 · Reply

Doozio Aug. 17 at 10:34 PM

$ACLX it’s so nice let’s mention it twice! 🐒🍌🧠⏰♾️

0 · Reply

hbwalk2 Aug. 15 at 11:21 PM

$ACLX Usually a good sign on a Friday. Not much option activity

0 · Reply

Doozio Aug. 15 at 1:05 AM

$ACLX new baker bro pos? They about to become da 🧠 brothers wen XBI 🎉 s.

0 · Reply

Doozio Aug. 14 at 7:51 PM

$ACLX out of the tightness after all da 🐑 been SPOT and da 🧠 is obviously spreading on the DLO while macro jabronis are calling for Thursday 🐑 corrections during 🐒🍌🧠⏰♾️

0 · Reply

hbwalk2 Aug. 13 at 4:57 PM

$ACLX Head fake at open Someone in the know perhaps taking or adding to large position. $ANAB and $AXSM also looking strong

0 · Reply

Falcones Aug. 13 at 4:57 PM

$ACLX Nice, who bought the dip today?

0 · Reply

d_risk Aug. 8 at 12:49 PM

$ACLX - Arcellx Inc. Common Stock - 10Q - Updated Risk Factors ACLX’s latest 10-Q risk factors overhaul highlights new threats from clinical trial variability, manufacturing and regulatory hurdles, reliance on Kite and third parties, global IP and patent uncertainties, expanded compliance and anti-corruption risks, market adoption and reimbursement challenges, and warns of major stock volatility, dilution, and large Gilead share resales. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ACLX/10-Q/2025-08-07

0 · Reply

justiceforb_85 Aug. 7 at 8:17 PM

$ACLX thoughts on this name? Anito-cel with excellent data but phase 3 read out several years away?

0 · Reply

hbwalk2 Aug. 5 at 4:03 PM

$ACLX Looking quite strong technically. Any good news about iMMagine with imminent earnings due will take stock much higher imo. Looking for low $80S

0 · Reply

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

BSX EW EXAS GH ISRG LLY MASI

Aug 7, 2025, 4:00 PM EDT - 16 days ago

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Jul 15, 2025, 4:51 PM EDT - 5 weeks ago

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

May 21, 2025, 4:00 PM EDT - 3 months ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma$

May 14, 2025, 9:30 AM EDT - 3 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 8, 2025, 4:00 PM EDT - 3 months ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 11:45 AM EDT - 4 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ISRG MASI MCK NTRA PEN TMO UNH

Apr 29, 2025, 11:30 AM EDT - 4 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

BSX DHR GKOS INSM ISRG LLY RDNT

Mar 20, 2025, 4:00 PM EDT - 5 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 18, 2025, 8:44 AM EDT - 5 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 17, 2025, 11:27 AM EDT - 5 months ago

Arcellx Impressive Safety Data Leaves Doubts

Feb 27, 2025, 4:00 PM EST - 6 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 26, 2025, 4:00 PM EST - 6 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Dec 9, 2024, 7:50 AM EST - 9 months ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition$

Dec 8, 2024, 11:00 PM EST - 9 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Nov 7, 2024, 4:00 PM EST - 10 months ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

$Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study$

Nov 5, 2024, 9:00 AM EST - 10 months ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Jun 26, 2024, 11:19 AM EDT - 1 year ago

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

May 9, 2024, 4:05 PM EDT - 1 year ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:05 PM EDT - 1 year ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences

Apr 4, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 20, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Feb 29, 2024, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Jan 30, 2024, 5:13 AM EST - 1 year ago

Arcellx: Navigating The CAR T-Cell Revolution

$Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH$

Dec 8, 2023, 4:00 PM EST - 1 year ago

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Nov 15, 2023, 1:44 PM EST - 1 year ago

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Nov 15, 2023, 6:23 AM EST - 1 year ago

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

GILD

Nov 15, 2023, 6:00 AM EST - 1 year ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD

Nov 15, 2023, 6:00 AM EST - 1 year ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD

Nov 13, 2023, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

$Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition$

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Aug 14, 2023, 4:00 PM EDT - 2 years ago

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Jun 19, 2023, 7:46 PM EDT - 2 years ago

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results

Apr 13, 2023, 4:01 PM EDT - 2 years ago

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Feb 21, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate in Upcoming Investor Conferences

Jan 30, 2023, 9:00 AM EST - 2 years ago

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Jan 9, 2023, 12:46 PM EST - 2 years ago

Arcellx: The Gilead Deal Derisks And Proves Their Technology

Dec 9, 2022, 8:46 AM EST - 2 years ago

Gilead to co-develop Arcellx's multiple myeloma drug

GILD

Dec 9, 2022, 8:17 AM EST - 2 years ago

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

$Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress$

Dec 9, 2022, 8:17 AM EST - 2 years ago

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Dec 9, 2022, 8:15 AM EST - 2 years ago

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

PivotSkull Aug. 23 at 4:36 AM

$ACLX Clinical stage immunology company with novel platform technology but pre-revenue and high cash burn

0 · Reply

Doozio Aug. 17 at 10:34 PM

$ACLX it’s so nice let’s mention it twice! 🐒🍌🧠⏰♾️

0 · Reply

hbwalk2 Aug. 15 at 11:21 PM

$ACLX Usually a good sign on a Friday. Not much option activity

0 · Reply

Doozio Aug. 15 at 1:05 AM

$ACLX new baker bro pos? They about to become da 🧠 brothers wen XBI 🎉 s.

0 · Reply

Doozio Aug. 14 at 7:51 PM

$ACLX out of the tightness after all da 🐑 been SPOT and da 🧠 is obviously spreading on the DLO while macro jabronis are calling for Thursday 🐑 corrections during 🐒🍌🧠⏰♾️

0 · Reply

hbwalk2 Aug. 13 at 4:57 PM

$ACLX Head fake at open Someone in the know perhaps taking or adding to large position. $ANAB and $AXSM also looking strong

0 · Reply

Falcones Aug. 13 at 4:57 PM

$ACLX Nice, who bought the dip today?

0 · Reply

d_risk Aug. 8 at 12:49 PM

0 · Reply

justiceforb_85 Aug. 7 at 8:17 PM

$ACLX thoughts on this name? Anito-cel with excellent data but phase 3 read out several years away?

0 · Reply

hbwalk2 Aug. 5 at 4:03 PM

$ACLX Looking quite strong technically. Any good news about iMMagine with imminent earnings due will take stock much higher imo. Looking for low $80S

0 · Reply

Fugazi_ Aug. 2 at 11:22 PM

$ACLX far out 90C bought, and 110C sold (12 day expiry). Very odd, very bullish.

1 · Reply

hbwalk2 Jul. 30 at 2:02 PM

$ACLX Breaking out firmly above 200 ma. Looking to get and stay above 74.66

0 · Reply

hbwalk2 Jul. 24 at 2:40 PM

$ACLX in the words of Steve Austin…”She’s Breaking up!! She’s Breaking up!!

0 · Reply

hbwalk2 Jul. 16 at 7:55 PM

$ACLX Sure feels like there is some news coming…

0 · Reply

hbwalk2 Jul. 9 at 6:18 PM

$ACLX sleeping giant has awakened. Looking for $73 Could go higher with News

1 · Reply

Quantumup Jul. 8 at 1:10 PM

Piper Sandler reiterated $ACLX OW-$115 $GILD $LEGN - $JNJ $BMY NVS GLPG Piper Sandler said in its note: "For several months, investors have been monitoring the competitive dynamic as $ACLX's anito-cel pivotal data started to emerge with two very important questions - does it have a differentiated safety profile on delayed neurotox and what is driving Carvykti's delayed neurotoxicity safety profile. A recent study was published in Nature Communications (Jul 2025) that reported a comparative analysis of patients treated with Carvytki and Abecma. While the study was limited in size (N=39), the results suggested that there are some unique aspects to Carvykti cell expansion. The dominant cell phenotype associated with Carvykti was effector-memory and Carvykti cells found in the cerebrospinal fluid primarily consisted of this phenotype. The study's authors suggest that they may partially drive both the delayed neurotoxicities and infections that are being reported with Caryvkti administration."

0 · Reply

justiceforb_85 Jun. 28 at 3:47 AM

$ACLX when is the next anticipated milestone for the company?

0 · Reply

JarvisFlow Jun. 17 at 12:00 PM

Citigroup has updated their rating for Arcellx ( $ACLX ) to Buy with a price target of 110.

0 · Reply

None_ Jun. 17 at 6:54 AM

$ACLX $GILD https://www.oncologypipeline.com/apexonco/eha-2025-arcellx-still-hopes-safety-will-trump-efficacy

0 · Reply

JarvisFlow Jun. 16 at 12:00 PM

HC Wainwright & Co. updates rating for Arcellx ( $ACLX ) to Buy, target set at 115.

0 · Reply

Falcones Jun. 12 at 12:29 PM

$ACLX Just finished my DD. Taking a long position today at open! Pipeline with their lead product looks very promising!

0 · Reply

hbwalk2 Jun. 4 at 4:33 PM

$ACLX 500 June 65 calls just traded. Oi is 1,100. No offsetting option trades detected. Interesting to see tomorrow is Oi shrinks

0 · Reply

Market Cap	3.98B
Revenue (ttm)	107.94M
Net Income (ttm)	-107.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-99.45%
Debt to Equity Ratio	0.00

Volume	454,700
Avg Vol	516,074
Day's Range	N/A - N/A
Shares Out	55.46M
Stochastic %K	58%
Beta	0.28
Analysts	Strong Sell
Price Target	$114.31